




## Pyridostigmine

Revised: December 19, 2022.

CASRN: 101-26-8



## Drug Levels and Effects

### Summary of Use during Lactation

Because of the low levels of pyridostigmine in breastmilk, amounts ingested by the infant are small and infant serum levels are very low. Pyridostigmine is not expected to cause any adverse effects in breastfed infants. Most mothers with myasthenia gravis are able to nurse successfully with pyridostigmine treatment, but occasionally breastfeeding must be discontinued to avoid excessive fatigue in the mother.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Drug Levels

*Maternal Levels.* A woman was taking pyridostigmine 120 mg every 4 to 5 hours for myasthenia gravis during pregnancy. After delivery, she had an undetectable (<100 mcg/L) pyridostigmine level in breastmilk 120 minutes after a 60 mg oral dose.[1]

A mother who was taking pyridostigmine 60 mg 3 times daily (3 mg/kg daily) had milk pyridostigmine levels ranging from 13 to 24 mcg/L at various times during the 8-hour dosage interval at 5 and 35 days postpartum. At 102 days postpartum while taking 40 mg twice daily (2 mg/kg daily), milk pyridostigmine levels ranged from the limit of detection (2 to 5 mcg/L) to 5 mcg/L during a dosage interval. The time of the peak milk level was about 4 hours after a dose. Another mother who was taking pyridostigmine 60 mg 5 times daily (5 mg/kg daily) had milk pyridostigmine levels of 25 and 22 mcg/L at the time of a dose and 2.5 hours after a dose, respectively, at 60 days postpartum. The authors estimated that an exclusively breastfed infant would receive a maximum of 0.1% of the maternal weight-adjusted dosage.[2]

*Infant Levels.* In an exclusively breastfed 60-day-old infant whose mother was taking pyridostigmine 60 mg 5 times daily (5 mg/kg daily), the drug was not detectable in serum (<2 mcg/L) at the time of a dose or 2.6 hours later.[2]

## Effects in Breastfed Infants

A woman was taking pyridostigmine 120 mg every 4 to 5 hours for myasthenia gravis. Her breastfed (extent not stated) infant reportedly thrived and had no cholinergic side effects.[1]

Two infants whose mothers were taking pyridostigmine 3 and 5 mg/kg daily during pregnancy and lactation were exclusively breastfed. Both infants gained weight and developed normally and had no signs of cholinergic side effects.[2]

## Effects on Lactation and Breastmilk

Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[3] and have variable effects on serum prolactin.[4] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

In a case series of 69 pregnancies in 65 women with myasthenia gravis over 27 years, 49 patients received pyridostigmine during pregnancy and lactation. Lactation data were available for 33 patients, and 25 of them nursed successfully, although the number of these mothers who were taking pyridostigmine was not given. Nursing was sometimes disrupted to avoid exhaustion in the mother.[5]

## Alternate Drugs to Consider

Neostigmine

## References

1. Skoglund RR, Roberts CC, Huddleston J. The role of anti-acetylcholine receptor antibody in neonatal myasthenia gravis. Bull Los Angeles Neurol Soc. 1978;43:66-9. PubMed PMID: 757366.
2. Hardell LI, Lindström B, Lönnerholm G, et al. Pyridostigmine in human breast milk. Br J Clin Pharmacol. 1982;14:565-7.
3. Clarke G, Fall CH, Lincoln DW, et al. Effects of cholinergic antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol. 1978;63:519-27. PubMed PMID: 566601.
4. Müller EE, Locatelli V, Cella S, et al. Prolactin-lowering and -releasing drugs: Mechanisms of action and therapeutic applications. Drugs. 1983;25:399-432. PubMed PMID: 6133737.

5. Djelmis J, Sostarko M, Mayer D, et al. Myasthenia gravis in pregnancy: Report on 69 cases. Eur J Obstet Gynecol Reprod Biol. 2002;104:21–5. PubMed PMID: 12128277.

## Substance Identification

### Substance Name

Pyridostigmine

### CAS Registry Number

101-26-8

### Drug Class

Breast Feeding

Lactation

Milk, Human

Cholinesterase Inhibitors

Parasympathomimetics